216 related articles for article (PubMed ID: 35816224)
21. Circumventing the side effects of L-asparaginase.
Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
[TBL] [Abstract][Full Text] [Related]
22. L-asparaginase from
Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
[TBL] [Abstract][Full Text] [Related]
23.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
24. What makes a good new therapeutic L-asparaginase?
Beckett A; Gervais D
World J Microbiol Biotechnol; 2019 Sep; 35(10):152. PubMed ID: 31552479
[TBL] [Abstract][Full Text] [Related]
25. L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.
Ramya LN; Doble M; Rekha VP; Pulicherla KK
Appl Biochem Biotechnol; 2012 Aug; 167(8):2144-59. PubMed ID: 22684410
[TBL] [Abstract][Full Text] [Related]
26. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
Modi T; Gervais D
Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
[TBL] [Abstract][Full Text] [Related]
27. Appraisal of cytotoxicity and acrylamide mitigation potential of L-asparaginase SlpA from fish gut microbiome.
Johny TK; Puthusseri RM; Saidumohamed BE; Sheela UB; Puthusseri SP; Sasidharan RS; Bhat SG
Appl Microbiol Biotechnol; 2022 May; 106(9-10):3583-3598. PubMed ID: 35579684
[TBL] [Abstract][Full Text] [Related]
28. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
Kelo E; Noronkoski T; Stoineva IB; Petkov DD; Mononen I
FEBS Lett; 2002 Sep; 528(1-3):130-2. PubMed ID: 12297292
[TBL] [Abstract][Full Text] [Related]
29. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
[TBL] [Abstract][Full Text] [Related]
30. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
32. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
33. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.
Zalewska-Szewczyk B; Gach A; Wyka K; Bodalski J; Młynarski W
Clin Exp Med; 2009 Jun; 9(2):113-6. PubMed ID: 19184328
[TBL] [Abstract][Full Text] [Related]
34. Asparaginase revisited.
van den Berg H
Leuk Lymphoma; 2011 Feb; 52(2):168-78. PubMed ID: 21281233
[TBL] [Abstract][Full Text] [Related]
35. Microbial L-asparaginase: purification, characterization and applications.
Muneer F; Siddique MH; Azeem F; Rasul I; Muzammil S; Zubair M; Afzal M; Nadeem H
Arch Microbiol; 2020 Jul; 202(5):967-981. PubMed ID: 32052094
[TBL] [Abstract][Full Text] [Related]
36. [Update on L-asparaginase treatment in paediatrics].
Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
[TBL] [Abstract][Full Text] [Related]
37. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a novel and glutaminase-free type II L-asparaginase from Corynebacterium glutamicum and its acrylamide alleviation efficiency in potato chips.
Chi H; Xia B; Shen J; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2022 Nov; 221():1384-1393. PubMed ID: 36130640
[TBL] [Abstract][Full Text] [Related]
39. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
40. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]